19 Mar

Why Analysts Still Favor Eli Lilly and Company Stock

WRITTEN BY Margaret Patrick

Analysts’ recommendations and target price

Wall Street analysts have set Eli Lilly and Company’s (LLY) 12-month consensus target price at $122, 2.59% lower than the company’s closing price on March 18. Despite this difference, analysts’ consensus recommendation for the stock remains a “buy.” In 2019, analysts have revised the company’s target price upward twice, from $117.73 in January to $120.07 in February and then to $122.00 in March.

To learn about what’s driving analysts to favor Eli Lilly in 2019, read What Are the Key Growth Drivers for Eli Lilly in Fiscal 2019?

Why Analysts Still Favor Eli Lilly and Company Stock

Of the 17 analysts covering Eli Lilly, two have given it “strong buys,” six have given it “buys,” and nine have given it “holds.”

On March 18, Eli Lilly closed at $125.24, 1.05% higher than its previous closing price, 68.08% higher than its 52-week low of $74.51, and 4.21% lower than its 52-week high of $130.75. The company’s market cap is $128.78 billion.

Based on its closing price on March 18, Eli Lilly has reported returns of 1.41% in the last week, 3.72% in the last month, and 9.04% in the last quarter. The company has reported returns of 17.51% in the last half year, 59.03% in the last year, and 8.23% year-to-date.

Change in structure

In September 2018, Eli Lilly divested ~20% of its stake in its animal health business, Elanco (ELAN), in an IPO. In February 2019, Eli Lilly initiated an exchange offer to completely divest its stake in Elanco. The company expects this deal to be almost tax-free for its shareholders.

On March 7, 2019, Eli Lilly issued a press release announcing the final exchange ratio of 4.5121 for the deal. On March 13, it issued another press release to announce that the exchange offer had been oversubscribed.

Following the successful completion of Elanco’s spin-off deal, Eli Lilly will be focusing exclusively on its human pharmaceutical business, which features robust growth assets such as Emgality, Verzenio, Olumiant, Lartruvo, Taltz, Basaglar, Jardiance, Trulicity, and Cyramza.

Latest articles

23 Jul

Will Fortinet Beat Q2 Earnings Estimates?

WRITTEN BY Aditya Raghunath

Leading cybersecurity company Fortinet (FTNT) is scheduled to announce its second-quarter earnings results on August 1. What should we expect?

Harley-Davidson’s Q2 earnings were slightly better than estimates.

Netflix (NFLX) has long relied on international markets to drive its streaming video business growth.

23 Jul

Could Ford’s Q2 Earnings Push Its Stock Even Higher?

WRITTEN BY Mohit Oberoi, CFA

Ford's second-quarter earnings results are scheduled for release on July 24. So far, Ford stock has outperformed its legacy peers.

23 Jul

Why RBC Isn't Optimistic about BlackBerry Stock

WRITTEN BY Aditya Raghunath

Shares of BlackBerry (BB) have been volatile over the last 12 months. BlackBerry stock fell 40.5% from $12.0 in September 2018 to $6.57 in December.

According to a Wall Street Journal report, Apple (AAPL) could be interested in buying Intel’s modem chip business.